Arvinas, Inc. (NASDAQ:ARVN) is among the best US stocks under $10 to invest in. XTX Topco Ltd has increased its stake in ...

Arvinas Inc. (NASDAQ:ARVN) is one of the best small cap stocks with biggest upside potential. On August 8, Arvinas, in ...

The global Targeted Protein Degradation Market, valued at US$0.01 billion in 2024, stood at US$0.48 billion in 2025 and is ...

There's been a notable change in appetite for Arvinas, Inc. (NASDAQ:ARVN) shares in the week since its quarterly report, with the stock down 15% to US$6.29. Revenue was dismal, with revenues of US$22m ...

Arvinas Inc. Annual stock financials by MarketWatch. View the latest ARVN financial statements, income statements and financial ratios.

Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements.

Arvinas' PROTAC approach has several advantages over conventional drugs, including the potential to target "undruggable" proteins, achieve tissue-specific targeting, and cross the blood-brain barrier.

Arvinas believes the differentiated pharmacology of ARV-471, including its iterative degradation activity, has the potential to translate into meaningful clinical benefit for patients.

The outperformance of Arvinas can be attributed to positive findings from a phase 1 study of its treatment for breast and prostate cancer. ARVN stock is also up 6x from levels of $13 seen in early ...

Arvinas is working toward a new class of drugs based on targeted protein degradation. The company is currently working on two major programs – ARV-471 and ARV-110 – which are developed using ...